Floatz logo

Rivogenlecleucel

Acute Bilineal Leukemia

Fred Hutchinson Cancer CenterCell therapyPhase 1Dormant
C
32/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
17/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Acute Bilineal Leukemia cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 2B
Venetoclax
M.D. Anderson Cancer Center
Phase 2B
Clofarabine
M.D. Anderson Cancer Center
Phase 2B
DEXAMETHASONE
M.D. Anderson Cancer Center
Phase 2B
Azacitidine
M.D. Anderson Cancer Center
Phase 2B

View all 14 →

Same molecule, other indications

Rivogenlecleucel is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
myelodysplastic syndromeDormant
CC
Indicative ·
44 / 100
View asset →
inborn error of immunityDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →